Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]